Trevi Therapeutics Reports Q4 and Full Year 2024 Financial Results and Provides Positive Clinical Updates

Trevi Therapeutics, Inc.

Announced positive topline data from Phase 2a RIVER trial in refractory chronic cough, meeting primary endpoint with 57% placebo-adjusted reduction in 24-hour cough frequency.
Completed enrollment in Phase 2b CORAL trial in IPF patients with chronic cough, topline data expected Q2 2025.
Sample size re-estimation for CORAL trial reaffirmed original sample size of 160 patients.
Ended 2024 with $107.6 million cash, expected runway into H2 2026.
Net loss for 2024 was $47.9 million, compared to $29.1 million in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.